ストックスクリーナーアプリを入手
113.05
2.07%
2.29
プレマーケット:
114.84
1.79
+1.58%
Cidara Therapeutics Inc (CDTX) 最新ニュース
Cidara Therapeutics Inc.’s volatility index tracking explainedCEO Change & Free High Return Stock Watch Alerts - newser.com
Using Ichimoku Cloud for Cidara Therapeutics Inc. technicals2025 AllTime Highs & Consistent Return Strategy Ideas - newser.com
What institutional flow reveals about Cidara Therapeutics Inc.Quarterly Trade Report & Verified Momentum Stock Alerts - newser.com
Cidara Therapeutics (NASDAQ:CDTX) Shares Gap Up on Analyst Upgrade - MarketBeat
Cidara Therapeutics (NASDAQ:CDTX) Now Covered by JPMorgan Chase & Co. - MarketBeat
JP Morgan Initiates Coverage on CDTX with Overweight Rating | CD - GuruFocus
WBB Securities Issues Positive Forecast for Cidara Therapeutics (NASDAQ:CDTX) Stock Price - MarketBeat
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza - sharewise.com
Cidara Therapeutics Analyst Says Lead Influenza Candidate Is 'Strategically Attractive' - Benzinga
Why Cidara Therapeutics (CDTX) Is Up 12.4% After Breakthrough Therapy Status for Novel Flu Drug CD388 - Yahoo Finance
Cidara Therapeutics (NASDAQ:CDTX) Hits New 12-Month High Following Analyst Upgrade - MarketBeat
Cidara Therapeutics (NASDAQ:CDTX) Price Target Raised to $150.00 - MarketBeat
Cidara Therapeutics Surges Ahead of ESWI 2025 Presentation and JP Morgan Coverage - Benzinga
Can machine learning forecast Cidara Therapeutics Inc. recovery2025 Geopolitical Influence & Intraday High Probability Alerts - newser.com
Cidara Therapeutics stock price target raised to $150 at H.C. Wainwright - Investing.com Canada
Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025 - The Manila Times
JP Morgan Initiates Coverage of Cidara Therapeutics (CDTX) with Overweight Recommendation - Nasdaq
How to build a dashboard for Cidara Therapeutics Inc. stockWeekly Risk Summary & AI Enhanced Trading Signals - newser.com
JPMorgan Initiates Coverage on Cidara Therapeutics With Overweight Rating, $200 Price Target - MarketScreener
Can Cidara Therapeutics Inc. (20D0) stock reach $200 price target2025 Major Catalysts & Fast Gain Stock Tips - newser.com
Forecasting Cidara Therapeutics Inc. price range with options data2025 Volatility Report & Stepwise Swing Trade Plans - newser.com
Biotech And Healthcare Stocks Hit 52-Week Highs: Is The Momentum Sustainable? - Nasdaq
Why Cidara Therapeutics Inc. stock could be next big winnerQuarterly Profit Summary & Long Hold Capital Preservation Tips - newser.com
Cidara Therapeutics' (CDTX) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Why Cidara Therapeutics Stock Crushed It Today - sharewise.com
HC Wainwright & Co. Maintains Cidara Therapeutics (CDTX) Buy Recommendation - Nasdaq
CDTX Surges on FDA's Breakthrough Therapy Designation - GuruFocus
Why Cidara Therapeutics Stock Crushed It Today - The Motley Fool
Cidara Therapeutics Surge: Time to Dive In? - StocksToTrade
FDA grants breakthrough therapy status to Cidara’s influenza drug By Investing.com - Investing.com Nigeria
CDTX Analyst Rating Update: WBB Securities Raises Price Target | - GuruFocus
Cidara Therapeutics stock hits 52-week high at 106.71 USD By Investing.com - Investing.com Nigeria
CDTX Achieves New Heights: What’s Next? - timothysykes.com
Cidara Therapeutics Granted FDA Breakthrough Therapy Designation For Flu-Preventing Antiviral - Stocktwits
Cidara wins FDA “Breakthrough” status for CD388 - The Pharma Letter
HC Wainwright Maintains Buy Rating on CDTX, Raises Price Target - GuruFocus
HC Wainwright Raises Cidara Therapeutics' Price Target to $150 From $110, Buy Rating Kept - MarketScreener
Cidara Therapeutics stock hits 52-week high at 106.71 USD - Investing.com India
Cidara Therapeutics (CDTX) Gains FDA Breakthrough Designation fo - GuruFocus
Cidara Therapeutics Receives FDA Breakthrough Therapy Designation for CD388 as Prophylactic Against Influenza A and B - Quiver Quantitative
Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy - GlobeNewswire
Breakthrough Therapy for CD388 Granted; Cidara Advances Phase 3 ANCHOR Trial Expanded to Older Adults - Stock Titan
What hedge fund moves indicate for Cidara Therapeutics Inc. (20D0) stock2025 Sector Review & Fast Exit/Entry Strategy Plans - newser.com
How Cidara Therapeutics Inc. (20D0) stock performs in volatility spikesJuly 2025 Sentiment & Weekly Market Pulse Alerts - newser.com
Is Cidara Therapeutics Inc a good long term investmentDividend Reinvestment Plans & Big Profit Low Investment - earlytimes.in
Cidara Therapeutics (NASDAQ:CDTX) Shares Up 5.5%Time to Buy? - MarketBeat
Cidara announces funding for non-vaccine flu preventive, CD388 - CIDRAP
How Cidara Therapeutics Inc. (20D0) stock reacts to Fed tightening2025 Volatility Report & Real-Time Chart Pattern Alerts - newser.com
How buyback programs support Cidara Therapeutics Inc. (20D0) stockCEO Change & Short-Term High Return Ideas - newser.com
Will Cidara Therapeutics Inc. outperform the marketBull Run & Low Drawdown Investment Ideas - newser.com
Biotech Stocks To Research – October 3rd - Defense World
Cidara Therapeutics (NASDAQ: CDTX) 2025 Investment Analysis – Will This Anti‑Flu Innovator Keep Soaring? - ts2.tech
JMP Securities Maintains Cidara Therapeutics (CDTX) Market Outperform Recommendation - Nasdaq
Cidara Therapeutics’ Surprise Surge: What Led the Charge? - timothysykes.com
Biotech Stocks To ResearchOctober 3rd - MarketBeat
Cidara Therapeutics (CDTX) Is Up 16.2% After $339 Million BARDA Award for Influenza Drug Acceleration - simplywall.st
5.74%
大文字化:
|
ボリューム (24 時間):